NasdaqGS:INVAPharmaceuticals
How Investors May Respond To Innoviva (INVA) Surging EPS From Continuing Operations
In February 2026, Innoviva, Inc. reported fourth-quarter 2025 revenue of US$114.61 million and net income of US$164.15 million, alongside full-year revenue of US$411.33 million and net income of US$271.17 million, all higher than the prior year.
An interesting feature of this release is the sharp increase in basic earnings per share from continuing operations, with quarterly EPS rising to US$2.19 and full-year EPS reaching US$4.02 compared with the previous year.
We’ll now explore how...